



Transparency notification

Brussels (Belgium), 15 December 2016 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 12 December 2016, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had increased and has crossed the 3% threshold.

On 9 December 2016, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 840 557 UCB shares with voting rights (versus 5 820 942 UCB shares in its previous notification dated 6 December 2016), representing 3.00% of the total number of shares issued by the company (194 505 658) (versus 2.99% in the notification dated 6 December 2016).

2. Content of the notification

The transparency notification dated 12 December 2016 included the following information:

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock International Limited	Exchange Place One, 1 Sempole Street, Edinburgh, EH3 8BL, U.K.
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan

- **Date on which the threshold is crossed:** 9 December 2016.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification		After the transaction		
	# of voting rights	# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc	0	0		0,00%	
BlackRock (Netherlands) B.V.	19.816	19.816		0,01%	
BlackRock (Singapore) Limited	7.217	7.217		0,00%	
BlackRock Advisors (UK) Limited	861.403	925.459		0,48%	
BlackRock Advisors, LLC	51.925	51.925		0,03%	
BlackRock Asset Management Canada Limited	61.015	61.015		0,03%	
BlackRock Asset Management Deutschland AG	219.382	222.966		0,11%	
BlackRock Asset Management North Asia Limited	644	644		0,00%	
BlackRock Financial Management, Inc.	81.434	81.434		0,04%	
BlackRock Fund Advisors	1.790.774	1.779.288		0,91%	
BlackRock Institutional Trust Company, National Association	2.073.162	2.066.009		1,06%	
BlackRock International Limited	16.385	14.159		0,01%	
BlackRock Investment Management (Australia) Limited	41.549	41.549		0,02%	
BlackRock Investment Management (UK) Limited	188.820	164.329		0,08%	
BlackRock Investment Management, LLC	237.515	237.515		0,12%	
BlackRock Japan Co., Ltd.	169.901	167.232		0,09%	
Subtotal	5.820.942	5.840.557		3,00%	
TOTAL		5.840.557	0	3,00%	0,00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Advisors (UK) Limited	Securities Lent			137.255	0,07%	physical
BlackRock Fund Advisors	Securities Lent			1.118	0,00%	physical
BlackRock Institutional Trust Company, National Association	Securities Lent			9.606	0,00%	physical
BlackRock Institutional Trust Company, National Association	Contract for Difference			69.408	0,04%	cash
BlackRock International Limited	Contract for Difference			12.199	0,01%	cash
BlackRock Investment Management (UK) Limited	Contract for Difference			183.921	0,09%	cash
BlackRock Japan Co., Ltd.	Securities Lent			1.400	0,00%	physical
TOTAL				414.907	0,21%	
TOTAL (A & B)				# of voting rights	% of voting rights	
				CALCULATE	6.255.464	3,22%

- **Chain of controlled undertakings through which the holding is effectively held:**

Please see the full chain of control in the PDF which is attached to the notification.

- **Additional information:**

The disclosure obligation arose due to voting rights for BlackRock, Inc. going above 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of €3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news